System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Guido Kobbe is an expert in Hematology at Düsseldorf University Hospital (Germany). As of October 2026, ScienceLeadR ranks Guido Kobbe in the top 1% of experts worldwide for Stem Cell Transplantation, Cell Transplantation and Leukemia. Guido Kobbe has authored 440 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 2 of them ongoing. SLR score: 1,500 (community average: 125). How the SLR is computed.

LeadR Profile

Guido Kobbe Düsseldorf University Hospital Germany
1 500 ScienceLeadR Reputation 1500

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Transplantation - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1997 - 2026
Source: PubMed

Heinrich Heine University Düsseldorf

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 440

Citations

Citations: 13 304 1st author: 18 Last author: 81 Unique author: 0

Main journals

Blood 121
Bone Marrow Transplant 32
Leuk Res 26
Ann Hematol 21
Biol Blood Marrow Transplant 20

Best Journals

J Clin Oncol 4
Nat Med 3
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Risk factors associated with prolonged treatment courses of chronic hepatitis E.
PMID 42932152 — ribavirin, hepatitis, chronic, viremia, retreatment, sex, risk factors, hepatitis e, therapeutics, infections, hepatitis		Infection20260
Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP.
PMID 42834113 — safety, microscopy, electron, scanning transmission, therapeutics, steroids		Bone Marrow Transplant20260
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.
PMID 42675139 — precursor cell lymphoblastic leukemia-lymphoma, incidence, leukemia, transplants, cost of illness		Leukemia20260
Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.
PMID 42660134 — neoplasms, therapeutics, digital health		Lancet Haematol20261
Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.
PMID 42657923 — cells, hematology, microscopy, electron, scanning transmission, incidence, lymphoma, b-cell, lymphoma, cyclophosphamide, stem cells, therapeutics, cell transplantation, conditioning, psychological, stem cell transplantation, t-lymphocytes, b-lymphocytes, transplantation, thiotepa, lymphoma, t-cell		Haematologica20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 11
Phase 2 4
N/A 2
Phase 1/Phase 2 2
Phase 2/Phase 3 1

By status:

Completed 13
Recruiting 4
Unknown 2
Terminated 1

By type:

Interventional 18
Observational 2

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 2
multicentric5to9 1
multicentricup10 11

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Double Blind Placebo Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chronic Graft Versus Host Disease (AXemplify 357)
2023-510292-65-00 — adrenal cortex hormones, graft vs host disease, transplants, therapeutics, bronchiolitis obliterans syndrome		Phase 3Recruiting2025
Venetoclax in Addition to Sequential Conditioning With Fludarabine Amsacrine Ara C (FLAMSA) Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS CMML or sAML
NCT05807932 — cells, myelodysplastic syndromes, safety, blood, microscopy, electron, scanning transmission, amsacrine, leukemia, myelomonocytic, chronic, cytarabine, leukemia, stem cells, leukemia, myeloid, acute, tacrolimus, leukemia, myeloid, behavior therapy, graft vs host disease, transplants, therapeutics, cell transplantation, conditioning, psychological, stem cell transplantation, transplantation, mycophenolic acid, bronchiolitis obliterans syndrome		Phase 1/Phase 2Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS